B · Normal
November 9th, Johnson & Johnson's pasritamig combination therapy achieved a prostate-specific antigen (PSA) response rate of 73% in a phase 1 clinical trial.
Related telegraphs
[CITIC Construction Investment: The pharmaceutical industry has entered an impro
11-08 21:38
[30 patents were awarded the China Patent Gold Award, covering high-end equipmen
11-07 14:55
[Gilead: The one-year persistence of lenacapavir administered once every six mon
11-07 01:19
On November 6th, Moderna's third-quarter earnings per share were 38 cents, and t
11-06 19:47
[Zhifei Bio: Pandemic influenza virus mRNA vaccine clinical trial application ac
11-06 16:13
[Zeproxitinib’s New Drug Application for the Treatment of Rheumatoid Arthritis A
11-06 12:42
Comments